brano 82

[brano 82 @82Brano64722]

@moinvests28

[brano 82 @82Brano64722]

@CryptocapoOO Quizás no llega al final del mes!! 😃

[brano 82 @82Brano64722]

@TheValueTrade + $ADUR 🫡

[brano 82 @82Brano64722]

@IberianTorero @CatalanTorero @kevinxu Que chulo el GIF

[brano 82 @82Brano64722]

@IberianTorero @kevinxu Ok gracias!! Compraré más.

[brano 82 @82Brano64722]

@ContraInvest También los precios en el supermercado están en una burbuja?

[brano 82 @82Brano64722]

@lorenzoramirez Tonterías de Lorenzo

[brano 82 @82Brano64722]

Bitcoin a la verga!! Ya se lo decía a Miquel hace años y me bloqueó pimpollo.

[Bitcoin al día. @BITCOIN_AL_DIA]

Análisis del mercado.
Retuitead por favor.
La bolsa sigue dividida entre tecnológicas y no tecnológicas. Bitcoin se sigue desplomando.
https://t.co/DJJGH3WG1F

[Makingmoneynow @makingmoneynow1]

$ADUR Insiders Put Their Own Money In:

When Vicus and Kampian Brought on the $ADUR Raise, they raised $21.20 CAD / $15.20 USD. When a company raises money, the one-word question I always ask is:
Did the people who know the most put their own money in? An outstanding offer at US$15.20 (CAD $21.20),
US$15.6M gross; Canaccord Genuity sole bookrunner; the answer is yes. According to SEDI filings, two insiders bought directly into the deal at the same price that institutions were paying:

Vicus, Ofer (Co-Founder, Chairman & CEO): +2,360 shares @ $21.20 CAD, ~$50,032. New direct balance: 9,794,875 shares (29% of the Company!!)
Peter Kampian (Director) +5,000 shares @
$21.20 CAD, $106,000. New balance: 26,970 shares.

Why this matters to me:

Both men wrote checks to a priced, arm’s-length financing package that included the same terms, the same dollars, the same risk: the same institutions’ books. Vicus already has the largest insider block on the register (~9.8M shares, the company’s single-largest aligned position) and holds c. 29% of the Company. He didn't need to add. He added anyway.

Kampian, a career financial executive (ex-CFO of Algonquin Income Fund and Mettrum, restructuring roles at PharmHouse and Muskoka), has been exactly that kind of person: one who, when working on the board, studies the balance sheet for a living. He bought it too.

The context that makes it more poignant:
The raise was raised to $15.20 USD, above the earlier weekly opening price of $14. That’s an up-priced book, institutional demand pushing the clearing price above where the stock was trading, not a discounted bailout.

The insiders who step in there are a vote that those who are closest to FOAK moving (Chemelot site, Ebert HERA permitting contract, EPC MOU, offtake LOI with a binding initial-parcel carve-out) believe $15.20 is not much with what’s ahead.

The bear-case honesty:
Insider buying isn’t a thesis in and of itself. The actual risks remain the same: scale-up execution at FOAK, a commercial license signed before the end of 2028, and avoiding multiple dilutive rounds at falling prices.

This raise was up-priced, mitigating the third concern in real time, but does not de-risk the first two. Those are answers to it, data- and steel-in-the-ground-only, not an SEDI filing. But alignment is a condition of trust in a small-cap management team, and Aduro keeps raising the bar. Insider ownership hovers at around 34%.

The CFO consistently performs and maintains the function. And now the Chairman/CEO and a finance veteran director are buying the open-market raise with the institutions themselves. That’s the sort of signal I carry quite a lot.

Long $ADUR . Not financial advice. DYOR.

[brano 82 @82Brano64722]

@Qantico_nxe IA tonterías

[brano 82 @82Brano64722]

@MiyagiCripto 0

[brano 82 @82Brano64722]

@AaronLiv_

[brano 82 @82Brano64722]

@IberianTorero

[The Value Trader @TheValueTrade]

$GRRR

[brano 82 @82Brano64722]

@TheLongInvest Allí vamos!!

[Nautilus Biotechnology @NautilusBio]

By studying the tau protein at the proteoform level, we firmly believe researchers will discover the mechanisms of neurodegeneration. You can be one of the first to study tau proteoforms with the Nautilus Tau Proteoforms Assay through participation in the Iterative Mapping Early Access Program.

In this blog post, we share some of the questions the assay may help answer. If you'd like to answer these or similar questions with the Nautilus Voyager™ Platform, we strongly encourage you to submit your project ideas through the Early Access Program.

https://t.co/fzaG1EuAjA

[The Long Investor @TheLongInvest]

Public announcement:

$ADUR is a position I will hold to see a 1000 X return

I will continue to chart this every day

This will be my masterpiece.

[brano 82 @82Brano64722]

@TheLongInvest Estoy contigo!!